Patents by Inventor Ann-Marie Pendergast

Ann-Marie Pendergast has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY
    Publication number: 20240058335
    Abstract: The present disclosure describes, in part, methods of preventing and/or treating cancer in a subject by co-administering an ABL inhibitor and a mevalonate pathway inhibitor.
    Type: Application
    Filed: January 7, 2022
    Publication date: February 22, 2024
    Applicant: Duke University
    Inventors: Ann Marie PENDERGAST, Jillian HATTAWAY LUTTMAN
  • Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
    Patent number: 11883401
    Abstract: The present disclosure provides compositions and methods for the treatment of pathogen-induced and/or chemical-induced lung injury, for regenerating lung epithelial cells following lung injury, for treating cancer, and for sensitizing a subject suffering from cancer to a chemotherapeutic agent.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: January 30, 2024
    Assignee: Duke University
    Inventors: Ann Marie Pendergast, Aaditya Khatri
  • Compositions for the Treatment of Pathogenic- And/Or Chemical-Induced Lung Injury and for the Treatment of Cancer and Methods of Using Same
    Publication number: 20200215066
    Abstract: The present disclosure provides compositions and methods for the treatment of pathogen-induced and/or chemical-induced lung injury, for regenerating lung epithelial cells following lung injury, for treating cancer, and for sensitizing a subject suffering from cancer to a chemotherapeutic agent.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Inventors: Ann Marie Pendergast, Aaditya Khatri
  • Compositions and methods for the treatment of cancer
    Patent number: 9931342
    Abstract: The present disclosure provides compositions and methods for the treatment of cancer, relating to the specific inhibition of Abelson (ABL) kinases.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: April 3, 2018
    Inventor: Ann Marie Pendergast
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
    Publication number: 20170216289
    Abstract: The present disclosure provides compositions and methods for the treatment of cancer, relating to the specific inhibition of Abelson (ABL) kinases.
    Type: Application
    Filed: February 2, 2017
    Publication date: August 3, 2017
    Applicant: Duke University
    Inventor: Ann Marie Pendergast
  • Method of treating infection with ABl tyrosine kinase inhibitors
    Patent number: 7384907
    Abstract: The present invention relates to a method of preventing or treating a pathogen infection comprising administering to a mammal in need thereof an effective amount of an inhibitor of Abl tyrosine kinase.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: June 10, 2008
    Assignee: Duke University
    Inventors: Ann Marie Pendergast, Elizabeth A. Burton
  • Method of blocking pathogen infection
    Publication number: 20050003377
    Abstract: The present invention relates, in general, to pathogens and, in particular, to a method of blocking pathogen infection and to a method of identifying agents suitable for use in such a method.
    Type: Application
    Filed: December 15, 2003
    Publication date: January 6, 2005
    Applicant: DUKE UNIVERSITY
    Inventors: Ann Marie Pendergast, Elizabeth Burton
  • Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
    Publication number: 20030092079
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
    Type: Application
    Filed: July 12, 2002
    Publication date: May 15, 2003
    Applicant: New York University/Duke University/Sugen Inc.
    Inventors: Joseph Schlessinger, Mikhail L. Gishizky, Ann Marie Pendergast
  • Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
    Patent number: 6528270
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: March 4, 2003
    Assignees: Sugen, Inc., Duke University, New York University
    Inventors: Joseph Schlessinger, Mikhail L. Gishizky, Ann Marie Pendergast
  • Abl-interactor protein
    Patent number: 6255074
    Abstract: The present invention relates to a protein that interacts with the cAb1 protein tyrosine kinase and to a nucleic acid sequence encoding same. The invention also relates to complexes of the protein of the invention and cAb1 and to the use of such complexes in the identification of therapeutic and diagnostic agents.
    Type: Grant
    Filed: July 8, 1998
    Date of Patent: July 3, 2001
    Assignee: Duke University
    Inventors: Ann-Marie Pendergast, Zonghan Dai
  • Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders
    Patent number: 6066463
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: May 23, 2000
    Assignees: New York University, Duke University, Sugen, Inc.
    Inventors: Joseph Schlessinger, Mikhail L. Gishizky, Ann Marie Pendergast
  • ABL-interactor protein
    Patent number: 5969101
    Abstract: The present invention relates to a protein that interacts with the cAbl protein tyrosine kinase and to a nucleic acid sequence encoding same. The invention also relates to complexes of the protein of the invention and cAbl and to the use of such complexes in the identification of therapeutic and diagnostic agents.
    Type: Grant
    Filed: October 27, 1995
    Date of Patent: October 19, 1999
    Assignee: Duke University
    Inventors: Ann Marie Pendergast, Zonghan Dai